TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26257041
Drug: Upper airway
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper airway stimulation (UAS) system implantation, fifth implant (n=10)
Study: 24184147
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) in adults (n=54)
Study: 24184147
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) in children (n=99)
Study: 24184147
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) in adults
Study: 23155007
Drug: W→G
Normalized name: Warfarin to Glyburide
Approvals — FDA: no, EMA: no, PMDA: no
Description: W→G
Study: 23155007
Drug: G→B
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G→B
Study: 23155007
Drug: B→G
Normalized name: Betamethasone-17-valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: B→G
Study: 11121919
Drug: Oral menadiol
Normalized name: MENADIOL
DrugBank: Menadiol diphosphate (DB14650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral menadiol 20 mg o.d. for 3 days (n=12)
Study: 11121919
Drug: Intravenous phytomenadione
Normalized name: phytomenadione
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phytomenadione 10 mg o.d. for 3 days (n=14)
Study: 9125681
Drug: Lacidipine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine, 4 mg daily
Study: 1607091
Drug: Oral lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lavage plus enemas
Study: 1607091
Drug: Oral lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lavage alone
Study: 2984617
Drug: Neo Sampoon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo Sampoon tablets
Study: 3689613
Drug: i.v. cimetidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. cimetidine 200 mg
Study: 3689613
Drug: i.v. ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ranitidine 50 mg
Study: 31058387
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in septic patients
Study: 28620941
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 75 g sucrose per day for 14 days
Study: 23786500
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention through hospital pharmacists
Study: 22981342
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of amoxicillin/clavulanic acid 1.2g intravenously every 8h for 24h, followed by 625 mg orally every 8h for 4 days
Study: 22981342
Drug: 1-day course
Normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day course of amoxicillin/clavulanic acid 1.2g intravenously every 8h for 24h, followed by placebo orally at the same time intervals
Study: 21544000
Drug: General +
Approvals — FDA: no, EMA: no, PMDA: no
Description: General + Specific Warm-Up (G + SWU)
Study: 18434903
Drug: N-acetylcysteine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 600 mg orally twice a day, from preoperative day 1 to postoperative day 1
Study: 11075310
Drug: RGD891 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RGD891 (60 micrograms/kg bolus dose + 336 micrograms/kg 8-h infusion)
Study: 11075310
Drug: RGD891 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: RGD891 (various intravenous regimens)
Study: 9146820
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg naloxone
Study: 9146820
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg buprenorphine and 0.1 mg naloxone in combination
Study: 8398324
Drug: STADMAX (scopolamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: STADMAX (scopolamine, tavegyl, ativan, dexamethasone, high dose maxolon)
Study: 8398324
Drug: SAD (serenace,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD (serenace, ativan, dexamethasone, low dose maxolon)
Study: 30244882
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation above 60 Gy EQD2
Study: 30244882
Drug: Concurrent or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent or sequential chemoradiation or radiation only
Study: 24855132
Drug: Cervical spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical spine and vestibular rehabilitation (treatment group)
Study: 20626608
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg or 50 mg
Study: 19039629
Drug: Micafungin 150
Normalized name: micafungin 150 MG in 150 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 150 mg
Study: 9332510
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg
Study: 16866136
Drug: Tribendimidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine (400 mg)
Study: 16866136
Drug: Tribendimidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine (300 mg)
Study: 16866136
Drug: Tribendimidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine (400 mg/day for 3 days)
Study: 16866136
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg/day for 3 days)
Study: 16866136
Drug: Tribendimidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine (200 mg)
Study: 16866136
Drug: Albendazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (200 mg)
Study: 8752294
Drug: Monovalent WC3
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent WC3 reassortant vaccine (serotype G1)
Study: 8752294
Drug: Quadrivalent WC3
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent WC3 reassortant vaccine (HRV G1, G2, G3, and P[8])
Study: 3931943
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine infusion (0.1 microgram/kg/min)
Study: 27368012
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (double-low protocol): 100 kVp tube voltage with 40% ASIR, iodixanol at 270 mg I/mL
Study: 27368012
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 120 kVp tube voltage with filtered back projection (FBP), iodixanol at 270 mg I/mL
Study: 27368012
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 120 kVp tube voltage with FBP, ioversol at 350 mg I/mL
Study: 22972216
Drug: Empowerment intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empowerment intervention (10 weekly hour-long sessions including group education and group discussion)
Study: 17501758
Drug: pegIFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegIFN plus RBV (1000 mg if body weight <75 kg and 1200 mg if >75 kg)
Study: 17501758
Drug: pegIFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegIFN plus RBV (1000-1200 mg/day)
Study: 17501758
Drug: pegIFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegIFN plus RBV (800 mg/day)
Study: 11448801
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid/day
Study: 7920074
Drug: H2-blocker therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2-blocker therapy with famotidine
Study: 7920074
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with bismuth, amoxicillin, and metronidazole
Study: 31567725
Drug: Extended prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended prophylactic nevirapine given daily from 6 weeks to 6 months
Study: 31567725
Drug: Maternal antiretroviral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal antiretroviral therapy exposure
Study: 27513639
Drug: Periosteal Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periosteal Stimulation Therapy (PST) with boosters and home exercise program
Study: 25053182
Drug: Levosimendan (LS)
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (LS) therapy
Study: 19535709
Drug: Personalized video‐assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized video‐assisted oral debriefing
Study: 9642436
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl at 40, 60, or 120 mg bid
Study: 1783533
Drug: Naloxone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (5 mg/kg loading dose over 10 minutes followed by 24-hour infusion at 3.5 mg/kg/h)
Study: 24016810
Drug: Licensed trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed trivalent influenza vaccine (TIV)
Study: 24016810
Drug: Investigational trivalent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational trivalent influenza vaccine (TIV)
Study: 18264759
Drug: Letrozole (prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (prolonged treatment beyond 3 months)
Study: 14730252
Drug: Clopidogrel in
Normalized name: Product containing clopidogrel in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel in combination with ASA
Study: 14730252
Drug: Long-term clopidogrel
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term clopidogrel therapy
Study: 14730252
Drug: Extended clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended clopidogrel therapy
Study: 11072147
Drug: PTA +
Normalized name: Achillea ptarmica whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTA + BT (intraarterial high-dose-rate brachytherapy)
Study: 2805828
Drug: 4 percent
Normalized name: LIDOCAINE 4 g in 100 g TOPICAL PATCH [Lidocaine 4 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 percent lidocaine (Xylocaine 4 percent topical)
Study: 2805828
Drug: 4 percent
Normalized name: LIDOCAINE 4 g in 100 g TOPICAL PATCH [Lidocaine 4 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 percent lidocaine (commercial preparation)
Study: 2805828
Drug: 4 percent
Normalized name: LIDOCAINE 4 g in 100 g TOPICAL PATCH [Lidocaine 4 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 percent preservative-free lidocaine solution
Study: 21256803
Drug: ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramelteon 8 mg
Study: 12762347
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone over 24 hours
Study: 11061530
Drug: Daily rGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rGH injections (Group A)
Study: 11061530
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly rGH injections (Group B)
Study: 11061530
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after 6 months of therapy
Study: 11061530
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after 12 months of therapy
Study: 8598549
Drug: RRR-alpha-tocopheryl acetate
Normalized name: RRR-alpha-tocopheryl acetate
DrugBank: D-alpha-Tocopherol acetate (DB14002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopheryl acetate (TA) 0 mg/d
Study: 8598549
Drug: RRR-alpha-tocopheryl acetate
Normalized name: RRR-alpha-tocopheryl acetate
DrugBank: D-alpha-Tocopherol acetate (DB14002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopheryl acetate (TA) 100 mg/d
Study: 8598549
Drug: RRR-alpha-tocopheryl acetate
Normalized name: RRR-alpha-tocopheryl acetate
DrugBank: D-alpha-Tocopherol acetate (DB14002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopheryl acetate (TA) 200 mg/d
Study: 8598549
Drug: RRR-alpha-tocopheryl acetate
Normalized name: RRR-alpha-tocopheryl acetate
DrugBank: D-alpha-Tocopherol acetate (DB14002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopheryl acetate (TA) 400 mg/d
Study: 4555773
Drug: A2/England/1/1966 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2/England/1/1966 vaccine (300 CCA)
Study: 4555773
Drug: A/equine 2/Miami/1963
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/equine 2/Miami/1963 vaccine (300 CCA)
Study: 26049123
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (60 mg/m²) and carboplatin (AUC 2.7) with prophylactic G-CSF (filgrastim) given on day 5 (and if needed on day 6)
Study: 26049123
Drug: Historical data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical data without routine use of prophylactic G-CSF
Study: 16769471
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone treatment
Study: 12897375
Drug: Euthyroid patients
Normalized name: Renthyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthyroid patients with positive thyroid antibody titers
Study: 9129557
Drug: Regular-strength grapefruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-strength grapefruit juice with 60 mg terfenadine
Study: 9129557
Drug: Double-strength grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-strength grapefruit juice with 60 mg terfenadine
Study: 9129557
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with 60 mg terfenadine
Study: 29356576
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Alpha-Lipoic Acid (ALA) per day for 1 month before surgery and for 2 months afterward
Study: 1828550
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate 10 mg daily (days 12-25)
Study: 6313501
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g guar gum
Study: 31380663
Drug: Borrowers showing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Borrowers showing greater positive arousal (e.g., excitement) in profile photos
Study: 28415937
Drug: Heparin saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin saline (50 IU/ml, 3 ml)
Study: 28415937
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (3 ml)
Study: 24390887
Drug: Enhanced feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced feedback (weight, BMI, blood pressure, homeostatic insulin resistance, nuclear magnetic resonance lipoprotein profiles at 2, 4, 7, and 10 months)
Study: 19276983
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alcoholic red wine (8.1±0.9 dl)
Study: 17445412
Drug: Intravenous Acehytisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acehytisine Hydrochloride (AHH) 4 mg/kg, iv.
Study: 17445412
Drug: Propafenone (PRO)
DrugBank: Propafenone (DB01182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propafenone (PRO) 1 mg/kg, iv.
Study: 17445412
Drug: Intravenous Acehytisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acehytisine Hydrochloride (AHH)
Study: 11176735
Drug: Sibutramine hydrochloride
Normalized name: Sibutramine Hydrochloride
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine hydrochloride alone (drug-alone group)
Study: 11176735
Drug: Sibutramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine plus group lifestyle modification (drug-plus-lifestyle group)
Study: 11176735
Drug: Sibutramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine plus portion-controlled diet (combined treatment group)
Study: 11176735
Drug: Drug-alone group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-alone group
Study: 11176735
Drug: Drug-plus-lifestyle and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-plus-lifestyle and combined treatment groups
Study: 9608581
Drug: Yohimbine (α2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (α2 antagonist)
Study: 8140046
Drug: Sandimmune (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune (300 mg) under fasting conditions
Study: 8140046
Drug: Sandimmune (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune (300 mg) after a high-fat meal
Study: 8140046
Drug: Sandimmune Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune Neoral (180 mg) under fasting conditions
Study: 8140046
Drug: Sandimmune Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune Neoral (180 mg) after a high-fat meal
Study: 3132732
Drug: Helium ion
Normalized name: Helium
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Helium ion radiation therapy
Study: 28405683
Drug: Bladder intracavitary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder intracavitary hyperthermic perfusion chemotherapy (BHPC)
Study: 28405683
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy alone
Study: 20967571
Drug: Exercise support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise support therapy (ST)
Study: 20967571
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (PT)
Study: 16498858
Drug: Topical cetirizine‐dinitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cetirizine‐dinitrate (2.44 mg per nasal cavity) delivered via nasal spray device
Study: 16498858
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline lavage before treatment)
Study: 10930904
Drug: RAC400 (rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC400 (rabeprazole 10 mg b.d., amoxycillin 750 mg b.d., clarithromycin 200 mg b.d.)
Study: 10930904
Drug: RAC800 (rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC800 (rabeprazole 10 mg b.d., amoxycillin 750 mg b.d., clarithromycin 400 mg b.d.)
Study: 1628727
Drug: Inhaled bradykinin
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bradykinin
Study: 8519379
Drug: Inhaled kallidin
Normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled kallidin
Study: 8519379
Drug: Inhaled [desArg9]-bradykinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled [desArg9]-bradykinin
Study: 8519379
Drug: Inhaled kallidin
Normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled kallidin after bradykinin challenge
Study: 8519379
Drug: Inhaled bradykinin
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bradykinin after kallidin challenge
Study: 8519379
Drug: Repeated exposures
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated exposures with inhaled [desArg9]-bradykinin
Study: 2958234
Drug: Commercial cream
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial cream for glass fibre itching
Study: 2958234
Drug: Fatty ointment
Normalized name: FATTY OINTMENT (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty ointment
Study: 2958234
Drug: Cream-ointment
Normalized name: Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream-ointment
Study: 15717460
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% with fentanyl 2.2 microg/ml
Study: 12707429
Drug: Pregabalin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (600 mg/day for creatinine clearance > 60 mL/min or 300 mg/day for creatinine clearance 30 to 60 mL/min)
Study: 1987228
Drug: Calcitonin gene-related
Normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin gene-related peptide infusion (16 ng/kg per min)
Study: 1987228
Drug: Calcitonin gene-related
Normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin gene-related peptide infusion
Study: 6342165
Drug: SAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAC plus 1 g ascorbic acid (Redoxon) daily for 6 months
Study: 6342165
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1 g intravenous injection)
Study: 29563289
Drug: Maraviroc monotherapy
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc monotherapy
Study: 26772807
Drug: Insulin analogues
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogues (AI) - insulin detemir and insulin aspart
Study: 26772807
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (HI) - NPH-insulin and regular HI
Study: 24910870
Drug: Retinyl retinoate-loaded
Normalized name: retinyl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl retinoate-loaded dissolving microneedle patches
Study: 24910870
Drug: Ascorbic acid-loaded
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid-loaded dissolving microneedle patches
Study: 27774730
Drug: Conventional thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional thrice weekly hemodialysis
Study: 12393661
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-1 receptor antagonist (IL-1Ra)
Study: 8657828
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol [Estraderm TTS (ETTS) 50 micrograms, applied twice weekly]